Jeffrey H. Murray

Array ( [id] => 11757203 [patent_doc_number] => 20170204071 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS' [patent_app_type] => utility [patent_app_number] => 15/324243 [patent_app_country] => US [patent_app_date] => 2015-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 17021 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15324243 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11554156 [patent_doc_number] => 20170100403 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'PEMETREXED DIPOTASSIUM FORMULATIONS' [patent_app_type] => utility [patent_app_number] => 15/310451 [patent_app_country] => US [patent_app_date] => 2015-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 4543 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15310451 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10468547 [patent_doc_number] => 20150353562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-10 [patent_title] => 'TYROSINE KINASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/741311 [patent_app_country] => US [patent_app_date] => 2015-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 75465 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14741311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11619705 [patent_doc_number] => 20170129893 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-11 [patent_title] => 'Novel Crystalline Form of Levomefolate' [patent_app_type] => utility [patent_app_number] => 15/319223 [patent_app_country] => US [patent_app_date] => 2015-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 2893 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15319223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12408447 [patent_doc_number] => 09969748 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Fused bicyclic heteroaromatic derivatives as kinase inhibitors [patent_app_type] => utility [patent_app_number] => 15/318422 [patent_app_country] => US [patent_app_date] => 2015-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20529 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 400 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15318422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10467084 [patent_doc_number] => 20150352099 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-10 [patent_title] => 'Compositions and Methods of Reducing Sedation' [patent_app_type] => utility [patent_app_number] => 14/730717 [patent_app_country] => US [patent_app_date] => 2015-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13131 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14730717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10489676 [patent_doc_number] => 20150374697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'ORGANIC COMPOUNDS' [patent_app_type] => utility [patent_app_number] => 14/730707 [patent_app_country] => US [patent_app_date] => 2015-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27946 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14730707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555167 [patent_doc_number] => 20170101412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'DIFLUOROETHYLPYRIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 15/315812 [patent_app_country] => US [patent_app_date] => 2015-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 31008 [patent_no_of_claims] => 38 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15315812 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10491126 [patent_doc_number] => 20150376146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'SODIUM CHANNEL BLOCKERS' [patent_app_type] => utility [patent_app_number] => 14/727189 [patent_app_country] => US [patent_app_date] => 2015-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 34242 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14727189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11805118 [patent_doc_number] => 09546129 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-17 [patent_title] => 'DTPA prodrugs, compositions thereof, and methods of using the same' [patent_app_type] => utility [patent_app_number] => 14/721552 [patent_app_country] => US [patent_app_date] => 2015-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 49 [patent_no_of_words] => 27950 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14721552 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12408423 [patent_doc_number] => 09969740 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-15 [patent_title] => Forms of a PI3K delta selective inhibitor for use in pharmaceutical formulations [patent_app_type] => utility [patent_app_number] => 15/313454 [patent_app_country] => US [patent_app_date] => 2015-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 9594 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15313454 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11560467 [patent_doc_number] => 09623027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'EGFR modulators and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/712794 [patent_app_country] => US [patent_app_date] => 2015-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 29 [patent_no_of_words] => 32838 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14712794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11560467 [patent_doc_number] => 09623027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'EGFR modulators and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/712794 [patent_app_country] => US [patent_app_date] => 2015-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 29 [patent_no_of_words] => 32838 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14712794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11560467 [patent_doc_number] => 09623027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'EGFR modulators and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/712794 [patent_app_country] => US [patent_app_date] => 2015-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 29 [patent_no_of_words] => 32838 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14712794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11560467 [patent_doc_number] => 09623027 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-04-18 [patent_title] => 'EGFR modulators and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/712794 [patent_app_country] => US [patent_app_date] => 2015-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 29 [patent_no_of_words] => 32838 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14712794 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11283720 [patent_doc_number] => 09499564 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'CDK inhibitors' [patent_app_type] => utility [patent_app_number] => 14/712582 [patent_app_country] => US [patent_app_date] => 2015-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 23031 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14712582 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11256799 [patent_doc_number] => 09481691 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-01 [patent_title] => 'CDK inhibitors' [patent_app_type] => utility [patent_app_number] => 14/712630 [patent_app_country] => US [patent_app_date] => 2015-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 23034 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14712630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11521617 [patent_doc_number] => 09605003 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-28 [patent_title] => 'Heterocyclic compounds and uses thereof' [patent_app_type] => utility [patent_app_number] => 14/710336 [patent_app_country] => US [patent_app_date] => 2015-05-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 82885 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14710336 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10354894 [patent_doc_number] => 20150239897 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-27 [patent_title] => 'PYRROLOPYRIMIDINE COMPOUNDS AS KINASE INHIBITORS' [patent_app_type] => utility [patent_app_number] => 14/708099 [patent_app_country] => US [patent_app_date] => 2015-05-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100061 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14708099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10347411 [patent_doc_number] => 20150232414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS' [patent_app_type] => utility [patent_app_number] => 14/704183 [patent_app_country] => US [patent_app_date] => 2015-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 63211 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14704183 [rel_patent_id] =>[rel_patent_doc_number] =>)